Scinovex
review Open AccessTop 1% cited

Advances and challenges in the treatment of lung cancer

Biomedicine & Pharmacotherapy · 2023 · Vol. 169 · pp. 115891–115891
Yuting LiBingshuo YanShiming He

Abstract

Lung cancer accounts for a relatively high proportion of malignant tumors. As the most prevalent type of lung cancer, non-small cell lung cancer (NSCLC) is characterized by high morbidity and mortality. Presently, the arsenal of treatment strategies encompasses surgical resection, chemotherapy, targeted therapy and radiotherapy. However, despite these options, the prognosis remains distressingly poor with a low 5-year survival rate. Therefore, it is urgent to pursue a paradigm shift in treatment methodologies. In recent years, the advent of sophisticated biotechnologies and interdisciplinary integration has provided innovative approaches for the treatment of lung cancer. This article reviews the cutting-edge developments in the nano drug delivery system, molecular targeted treatment system, photothermal treatment strategy, and immunotherapy for lung cancer. Overall, by systematically summarizing and critically analyzing the latest progress and current challenges in these treatment strategies of lung cancer, we aim to provide a theoretical basis for the development of novel drugs for lung cancer treatment, and thus improve the therapeutic outcomes for lung cancer patients.

Nanoplatforms for cancer theranosticsImmunotherapy and Immune ResponsesCancer Research and TreatmentsLung cancerMedicineTreatment of lung cancerRadiation therapyIntensive care medicineCancerImmunotherapyTargeted therapyChemotherapyOncology

MeSH terms

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungHumansImmunotherapyLung Neoplasms
Citations
376
FWCI
41.13
field-weighted impact
References
284
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Advances and challenges in the treatment of lung cancer · Scinovex